Top-Rated StocksTop-RatedNASDAQ:JAZZ Jazz Pharmaceuticals (JAZZ) Stock Price, News & Analysis $232.35 -5.93 (-2.49%) Closing price 09/29/2026 04:00 PM EasternExtended Trading$232.36 +0.00 (+0.00%) As of 09/29/2026 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Jazz Pharmaceuticals Stock (NASDAQ:JAZZ) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Jazz Pharmaceuticals alerts:Sign Up Key Stats Today's Range$229.16▼$238.0050-Day Range$232.35▼$261.6252-Week Range$128.49▼$266.38Volume777,175 shsAverage Volume710,015 shsMarket Capitalization$15.08 billionP/E Ratio16.02Dividend YieldN/APrice Target$289.37Consensus RatingBuy Company Overview Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for patients with serious neurological and oncology-related conditions. Founded in 2003 and headquartered in Dublin, Ireland, the company operates internationally, with a significant commercial presence in the United States and other markets. Jazz’s neuroscience portfolio includes Xywav and Xyrem, which contain oxybate and are used to treat narcolepsy-related symptoms; Xywav is also approved for idiopathic hypersomnia in adults. The company also markets Epidiolex, a cannabidiol-based medicine for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome and tuberous sclerosis complex in applicable markets. In oncology and hematology, Jazz offers products including Rylaze for acute lymphoblastic leukemia and lymphoblastic lymphoma, Vyxeos for certain cases of acute myeloid leukemia, Zepzelca for metastatic small cell lung cancer in the United States, and Defitelio for hepatic veno-occlusive disease following hematopoietic stem-cell transplantation. Jazz expanded its neuroscience business through the acquisition of GW Pharmaceuticals in 2021. The company was co-founded by Bruce Cozadd, who has served as its chair and chief executive officer.AI Generated. May Contain Errors. Read More Jazz Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks85th Percentile Overall ScoreJAZZ MarketRank™: Jazz Pharmaceuticals scored higher than 85% of companies evaluated by MarketBeat, and ranked 63rd out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingJazz Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 strong buy rating, 17 buy ratings, 1 hold rating, and no sell ratings.Upside PotentialJazz Pharmaceuticals has a consensus price target of $289.37, representing about 24.5% upside from its current price of $232.35.Amount of Analyst CoverageJazz Pharmaceuticals has been the subject of 15 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Jazz Pharmaceuticals' stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth2.64% Earnings GrowthEarnings for Jazz Pharmaceuticals are expected to grow by 2.64% in the coming year, from $21.61 to $22.18 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Jazz Pharmaceuticals is 16.02, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.45.Price to Earnings Ratio vs. SectorThe P/E ratio of Jazz Pharmaceuticals is 16.02, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 273.78.Price to Earnings Growth RatioJazz Pharmaceuticals has a PEG Ratio of 0.21. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioJazz Pharmaceuticals has a P/B Ratio of 3.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Jazz Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.51% of the float of Jazz Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverJazz Pharmaceuticals has a short interest ratio ("days to cover") of 7.22.Change versus previous monthShort interest in Jazz Pharmaceuticals has recently increased by 1.13%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldJazz Pharmaceuticals does not currently pay a dividend.Dividend GrowthJazz Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.0 / 5News Sentiment0.27 News SentimentJazz Pharmaceuticals has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Jazz Pharmaceuticals this week, compared to 8 articles on an average week.Search InterestOnly 9 people have searched for JAZZ on MarketBeat in the last 30 days. This is a decrease of -10% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Jazz Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Jazz Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $24,443,842.00 in company stock.Percentage Held by Insiders4.10% of the stock of Jazz Pharmaceuticals is held by insiders.Percentage Held by Institutions89.14% of the stock of Jazz Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Jazz Pharmaceuticals' insider trading history. Receive JAZZ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Jazz Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. JAZZ Stock News HeadlinesHead to Head Review: Zoetis (NYSE:ZTS) vs. Jazz Pharmaceuticals (NASDAQ:JAZZ)September 29 at 4:29 AM | americanbankingnews.comJAZZ Stock Earnings Estimates Decreased by Zacks ResearchSeptember 28 at 1:13 AM | americanbankingnews.comTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years. While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million. One company controls the entire supply chain behind this discovery. | Behind the Markets (Ad)Bernstein Reaffirms Their Hold Rating on Jazz Pharmaceuticals (JAZZ)September 27 at 12:09 AM | theglobeandmail.comJazz Pharmaceuticals (NASDAQ:JAZZ) Research Coverage Started at The Goldman Sachs GroupSeptember 27 at 2:32 AM | americanbankingnews.comJazz Pharmaceuticals (NASDAQ:JAZZ) EVP Neena Patil Sells 1,200 Shares of StockSeptember 15, 2026 | insidertrades.comRenee Gala Sells 2,000 Shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) StockSeptember 11, 2026 | insidertrades.comJazz Pharmaceuticals (NASDAQ:JAZZ) Director Bruce Cozadd Sells 6,000 Shares of StockSeptember 3, 2026 | insidertrades.comSee More Headlines JAZZ Stock Analysis - Frequently Asked Questions How have JAZZ shares performed this year? Jazz Pharmaceuticals' stock was trading at $170.00 at the beginning of 2026. Since then, JAZZ shares have increased by 36.7% and is now trading at $232.35. How were Jazz Pharmaceuticals' earnings last quarter? Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) announced its quarterly earnings results on Monday, August, 3rd. The specialty pharmaceutical company reported $5.71 earnings per share for the quarter, missing analysts' consensus estimates of $6.18 by $0.47. Jazz Pharmaceuticals's quarterly revenue was up 15.5% compared to the same quarter last year. Read the conference call transcript. Does Jazz Pharmaceuticals have any subsidiaries? Jazz Pharmaceuticals subsidiaries include Cavion. How do I buy shares of Jazz Pharmaceuticals? Shares of JAZZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Jazz Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Jazz Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Adobe (ADBE), Advanced Micro Devices (AMD), Arista Networks (ANET) and ServiceNow (NOW). Company Calendar Last Earnings8/03/2026Today9/29/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (13m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 JAZZ's financial health is in the Green zone, according to TradeSmith. JAZZ has been in this zone for over 13 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:JAZZ CIK1232524 Webwww.jazzpharma.com Phone(531) 634-7800Fax353-1634-7850Employees2,890Year Founded2003Price Target and Rating Average Price Target for Jazz Pharmaceuticals$289.37 High Price Target$337.00 Low Price Target$225.00 Potential Upside/Downside+24.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage19 Analysts Profitability EPS (Trailing Twelve Months)$14.50 Trailing P/E Ratio16.02 Forward P/E Ratio10.75 P/E Growth0.21Net Income-$356.15 million Net Margins20.45% Pretax Margin15.82% Return on Equity33.97% Return on Assets13.02% Debt Debt-to-Equity Ratio0.69 Current Ratio1.78 Quick Ratio1.58 Sales & Book Value Annual Sales$4.27 billion Price / Sales3.53 Cash Flow$15.86 per share Price / Cash Flow14.65 Book Value$71.07 per share Price / Book3.27Miscellaneous Outstanding Shares64,920,000Free Float62,253,000Market Cap$15.08 billion OptionableOptionable Beta0.36 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NASDAQ:JAZZ) was last updated on 9/30/2026 by MarketBeat.com Staff. From Our PartnersI've seen this movie before (last time: 17,556%)My track record speaks for itself... KDA: 17,556%. PRE: 3,900%. OCEAN: 2,650%. Every single one was called ...Crypto 101 Media | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredWhy I went to Mount RushmoreA small miner just hit on gold in the hills surrounding Mount Rushmore, thanks to a breakthrough new technolog...Stansberry Research | SponsoredBezos… DOOMEDA single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...Paradigm Press | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredShould You Convert a Traditional IRA to a Roth After 60?Considering a Roth conversion after 60? The upside includes no income limits on conversions, potential tax-fre...SmartAsset | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jazz Pharmaceuticals PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Jazz Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
